

1229716

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

September 23, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/497,590
FILING DATE: August 25, 2003
RELATED PCT APPLICATION NUMBER: PCT/US04/27540

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

16563 U.S. PTO
08/25/03

Please type a plus sign (+) inside this box →

+

PTO/SB/16 (5-03)
Approved for use through 4/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a requ st for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

16563 U.S. PTO
08/25/03

08/25/03

INVENTOR(S)					
Given Name (first and middle (if any))	Family Name or Surname	Residence (City and either State or Foreign Country)			
Eduardo J. John Jeffrey	Martinez Talley	Boston, MA Somerville, MA			
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">23405</div> <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;"> Place Customer Number Bar Code Label here </div>		OR Type Customer Number here			
<input checked="" type="checkbox"/> Firm or Individual Name <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">HESLIN ROTHENBERG FARLEY & MESITI P.C.</div>		Address <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">5 Columbia Circle</div>			
Address		Address			
City	Albany	State	New York	ZIP	12203
Country	USA	Telephone	618-452-5600	Fax	618-452-5579
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">57</div>		<input type="checkbox"/> CD(s), Number <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;"></div>			
<input type="checkbox"/> Drawing(s) Number of Sheets <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;"></div>		<input type="checkbox"/> Other (specify) <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;"></div>			
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$)			
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees		<div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">08-1935</div> <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">\$80.00</div>			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

Philip E. Hanseh

TYPED or PRINTED NAME Philip E. Hanseh

TELEPHONE

518-452-5600

Date

08-25-03

REGISTRATION NO.

32,700

(if appropriate)

Docket Number:

2221.004

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

P1MALL/REV05

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Applicant: Martinez et al.

Title: QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES

Attorney Docket No.: 2221.004

"EXPRESS MAIL" Mailing Label No.: EV 185212672 US

Date of Deposit: August 25, 2003

Enclosed are:

- * Express Mail Certificate - Label No.: **EV 185212672 US**
- * One (1) Acknowledgment Postcard
- * Check for \$80.00 (Provisional Patent Application filing fee) (Small Entity)
- * Provisional Application for Patent Cover Sheet (1 page) (Small Entity)
- * Provisional Patent Application (57 pages)
- * Application Data Sheet (2 pages)


37 CFR 1.10 Certification

I hereby certify that this paper and the indicated enclosures are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to:

Mail Stop Provisional Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Chris Weber

(Typed or printed name of person mailing paper or fee)

A handwritten signature in cursive script, appearing to read "Chris Weber", written over a horizontal line.

(Signature of person mailing paper or fee)

QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES

Field of the Invention


[001] The invention relates to a chemical genus of quaternary salt derivatives of 1,4-diphenylazetidin-2-ones useful for the treatment of hypercholesterolemia.

Background of the Invention


[002] 1,4-Diphenylazetidin-2-ones and their utility for treating disorders of lipid metabolism are described in US patent 6,498,156 and PCT application WO02/50027, the disclosures of which are incorporated herein by reference.

Summary of the Invention

[003] In one aspect the invention relates to compounds of the general formulae:



or



wherein

R^1 and R^2 are chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl, lower aminoalkyl, alkylsulfonyl, arylsulfonyl, a sugar, a glucuronide and a sugar carbamate;

R^3 is chosen from H, -OH, fluoro and -O-loweralkyl;

R^{3a} is chosen from H and fluoro, or R^{3a} and R^3 together are =O;

R^4 is chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl and lower aminoalkyl, alkylsulfonyl, arylsulfonyl;

Q is chosen from a direct bond, -O-, -S-, -NH-, -CH₂O-, -CH₂NH-, -C(=O)-, -CONH-, -NHCO-, -O(C=O)-, -(C=O)O-, -NHCONH-, -OCONH- and -NHCOO- ;

A is chosen from C₂ to C₂₀ hydrocarbon, substituted alkyl of 2 to 20 carbons, substituted aryl, substituted arylalkyl, and oxaalkyl of four to fifty carbons; and, when Q is a direct bond, -

C(=O) or -O(C=O)-, A may additionally be methylene;

R⁵ forms a five- to seven-membered ring with A or R⁶;


R⁶ is alkyl, forms a double bond with A or forms a five- to seven-membered ring with R⁵;

R⁷ is alkyl or together with R⁵ or R⁶ forms a second five- to seven-membered ring; and


when Q is not -O- or -CH₂NH-, R⁵, may additionally be alkyl or aryl; and

X is an anion.

[004] In a second aspect the invention relates to compounds that may be thought of as isomeric “dimers” of the foregoing quats, namely isomers of formulae III, IV and V:




III



IV

and



in which the substituents are as defined before, and Y is chosen from C₂ to C₂₀ hydrocarbon, substituted alkyl of 2 to 20 carbons, substituted arylalkyl and oxaalkyl of four to fifty carbons; R⁶ and R^{6a} are alkyl or together with Y form a first five- to seven-membered ring; R⁷ and R^{7a} are alkyl or together form a second five- to seven-membered ring; and X₂ is either a dianion or two monoanions.

[005] In a third aspect the invention relates to pharmaceutical formulations comprising a pharmaceutically acceptable carrier and a compound as above having a pharmaceutically acceptable counter anion and, optionally additionally comprising an inhibitor of cholesterol biosynthesis and/or a compound that normalizes lipid metabolism.

[006] In a fourth aspect, the invention relates to methods for treating a disorder of lipid metabolism, including hyperlipidemia and arteriosclerotic symptoms; inhibiting the absorption of cholesterol from the intestine; reducing the blood plasma or serum concentrations of LDL cholesterol; reducing the concentrations of cholesterol and cholesterol ester in the blood plasma or serum; reducing blood plasma or serum concentrations of C-reactive protein (CRP), reducing blood plasma or serum concentrations of triglycerides; reducing blood plasma or serum concentrations of

apolipoprotein B; increasing blood plasma or serum concentrations of high density lipoprotein (HDL) cholesterol; increasing the fecal excretion of cholesterol; treating a clinical condition for which a cholesterol absorption inhibitor is indicated and reducing the incidence of coronary heart disease-related events. The methods comprise administering a compound described herein.


Detailed description of the Invention

[007] Compounds of the genera I-V above are inhibitors of cholesterol absorption from the intestine. As such they have utility in treating and preventing lipid disorders, such as hypercholesterolemia and hyperlipidemia. Because of their effect in lowering serum lipids, the compounds are useful in the treatment and prevention of atherosclerosis. The compounds can be used advantageously in combination with other hypolipidemic agents, including inhibitors of cholesterol biosynthesis, such as the HMG-CoA reductase inhibitors. Preferred HMG-CoA reductase inhibitors would include the "statins": lovastatin, simvastatin, pravastatin, rosuvastatin and fluvastatin. A further listing of non-limiting examples of antihyperlipidemic agents that may be used in combination with the compounds of the present invention may be found in columns 5-6 of US patent 6,498,156, the disclosure of which is incorporated herein by reference.


[008] Compounds of the invention have the advantage that they suppress serum cholesterol and/or LDL levels but the compounds themselves are not appreciably absorbed into the mammalian circulation upon oral administration. As a result of the low-to-insignificant serum levels, fewer side-effects, such as drug-drug interactions, are observed.

[009] Within the genus of the invention, subgenera include (a) those in which R^7 forms a second six-membered ring; (b) those in which -Q-A- is chosen from $(C_2 \text{ to } C_{20})$


hydrocarbon), -O-(C₂ to C₂₀ hydrocarbon), -NH(C₂ to C₂₀ hydrocarbon), -NHCO(C₂ to C₂₀ hydrocarbon) and oxaalkyl of four to fifty carbons; (c) those in which R¹ and R² are H, halogen, -OH, or methoxy; R³ is -OH; and R⁴ is fluoro; (d) those in which R¹ and R² are chosen from a sugar, a glucuronide and a sugar carbamate; R³ is -OH; and R⁴ is fluoro;

and (e) those in which -Q-A- is 


[0010] One preferred subgenus of genera I and II is that in which R⁵, R⁶ and R⁷ taken together form a diazabicyclooctane quat:




[0011] A subgenus of genera III, IV and V is that in which R⁶ and R^{6a} taken together with Y form a dialkyl piperazininium bisquat:





[0012] A further subgenus of genera III, IV and V related to the dialkyl piperazininium bisquats is that in which R⁶, R^{6a}, R⁷ and R^{7a} taken together with Y form a diazabicyclooctane bisquat:




[0013] Another preferred subgenus of genera I and II is that in which R^5 , R^6 and R^7 taken together form a quinuclidinium quat:



[0014] Exemplary compounds of the invention include:



and



[0015] Other subgenera of genera I and II are those in which R^5 forms a five- to seven-membered ring with A, R^6 forms a double bond with A and R^7 is alkyl.

[0016] The compounds of the invention are quaternary salts, i.e. cationic species. Therefore they will always be presented as salts, and the term "pharmaceutically acceptable salt" refers to salts whose counter ion (anion) derives from pharmaceutically acceptable non-toxic acids including inorganic acids, organic acids and water (which formally furnishes the hydroxide anion). Suitable pharmaceutically acceptable anions for the compounds of the present invention include hydroxide, acetate, benzenesulfonate (besylate), benzoate, bicarbonate, bisulfate, carbonate, camphorsulfonate, citrate, ethanesulfonate, fumarate, gluconate, glutamate, bromide, chloride, isethionate, lactate, maleate, malate, mandelate, methanesulfonate, mucate, nitrate, pamoate, pantothenate, phosphate, succinate, sulfate, tartrate, p-toluenesulfonate, and the like. The desired salt may be obtained by ion exchange of whatever counter ion is obtained in the synthesis of the quat. These methods are well known to persons of skill. Although pharmaceutically acceptable counter ions will be preferred for preparing pharmaceutical formulations, other anions are quite acceptable as synthetic intermediates. Thus X may be pharmaceutically undesirable anions, such as iodide, oxalate, trifluoromethanesulfonate and the like, when such salts are chemical intermediates. When the compounds of the invention are bisquats, one may employ as counter ions either two monoanionic species (e.g. Cl_2) or a single dianionic species (e.g. fumarate). Similarly, one could employ oligoanionic species and make salts having appropriate ratios of quat to counterion, such as $(quat)_3$ citrates. These would be obvious equivalents.

Definitions

[0017] Throughout this specification the terms and substituents retain their definitions.

[0018] Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. Lower alkyl refers to alkyl groups of from 1 to 6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl and the like. Preferred alkyl groups are those of C₂₀ or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like.

[0019] C₁ to C₂₀ Hydrocarbon includes alkyl, cycloalkyl, alkenyl, alkynyl, aryl and combinations thereof. Examples include phenethyl, cyclohexylmethyl, camphoryl and naphthylethyl.

[0020] Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.

[0021] Oxaalkyl refers to alkyl residues in which one or more carbons (and their associated hydrogens) have been replaced by oxygen. Examples include methoxypropoxy, 3,6,9-trioxadecyl and the like. The term oxaalkyl is intended as it is understood in the art [see Naming and Indexing of Chemical Substances for Chemical Abstracts, published by the American Chemical Society, ¶196, but without the restriction of ¶127(a)], i.e. it refers to compounds in which the oxygen is bonded via a single bond to its adjacent atoms

(forming ether bonds). Similarly, thiaalkyl and azaalkyl refer to alkyl residues in which one or more carbons have been replaced by sulfur or nitrogen, respectively. Examples include ethylaminoethyl and methylthiopropyl.

[0022] Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, *t*-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to four carbons.

[0023] Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. Aromatic 6- to 14-membered carbocyclic rings include, *e.g.*, benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, *e.g.*, imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.

[0024] Arylalkyl means an alkyl residue attached to an aryl ring. Examples are benzyl, phenethyl and the like.

[0025] Substituted alkyl, aryl, cycloalkyl, heterocyclyl etc. refer to alkyl, aryl, cycloalkyl, or heterocyclyl wherein up to three H atoms in each residue are replaced with halogen,


haloalkyl, hydroxy, loweralkoxy, carboxy, carboalkoxy (also referred to as alkoxy-carbonyl), carboxamido (also referred to as alkylaminocarbonyl), cyano, carbonyl, nitro, amino, alkylamino, dialkylamino, mercapto, alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, or heteroaryloxy.

[0026] The term "halogen" means fluorine, chlorine, bromine or iodine.

[0027] The term "sugar" is used in its normal sense, as defined in Hawley's Condensed Chemical Dictionary, 12th Edition, Richard J. Lewis, Sr.; Van Nostrand Reinhold Co. New York. It encompasses any carbohydrate comprised of one or two saccharose groups. The monosaccharide sugars (often called simple sugars) are composed of chains of 2-7 carbon atoms. One of the carbons carries aldehydic or ketonic oxygen, which may be combined in acetal or ketal forms. The remaining carbons usually have hydrogen atoms and hydroxyl groups. Among monosaccharides which would be considered within the term "sugars" as intended in this application, are arabinose, ribose, xylose, ribulose, xylulose, deoxyribose, galactose, glucose, mannose, fructose, sorbose, tagatose, fucose, quinovose, rhamnose, manno-heptulose and sedoheptulose. Among the disaccharides are sucrose, lactose, maltose, and cellobiose. Unless specifically modified, the general term "sugar" refers to both D-sugars and L-sugars.


[0028] The term "glucuronide" is also used in its normal sense to refer to a glycoside of glucuronic acid.


[0029] The term "sugar carbamate" refers to mono-, di- and oligosaccharides in which one or more hydroxyls have been derivatized as carbamates, particularly as phenyl carbamates and substituted phenyl carbamates. [See Detmers et al. Biochim Biophys. Acta 1486, 243-252 (2000), which is incorporated herein by reference.] A preferred sugar carbamate is:



[0030] The term "prodrug" refers to a compound that is made more active *in vivo*. Since the compounds of the invention are minimally absorbed into the systemic circulation, activation *in vivo* may come about by chemical action or through the intermediacy of enzymes and microflora in the GI tract.

[0031] In the characterization of the variables, it is recited that R^5 may form a five- to seven-membered ring with A or R^6 ; that R^6 may form a double bond with A or may form a five- to seven-membered ring with R^5 ; and that R^7 may form a second five- to seven-membered ring. It is intended that these rings may exhibit various degrees of unsaturation (from fully saturated to aromatic), may include heteroatoms and may be substituted with lower alkyl or alkoxy. Examples of the $-A-NR^5R^6R^7$ residue that fall within this subgenus include:





[0032] The terms “methods of treating or preventing” mean amelioration, prevention or relief from the symptoms and/or effects associated with lipid disorders. The term “preventing” as used herein refers to administering a medicament beforehand to forestall or obtund an acute episode. The person of ordinary skill in the medical art (to which the present method claims are directed) recognizes that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a condition, and this is the sense intended in applicants’ claims. As used herein, reference to “treatment” of a patient is


intended to include prophylaxis. Throughout this application, various references are referred to within parentheses or square brackets. The disclosures of these publications in their entireties are hereby incorporated by reference as if written herein.

[0033] The term "mammal" is used in its dictionary sense. Humans are included in the group of mammals, and humans would be the preferred subjects of the methods of treatment.

[0034] The compounds described herein contain two or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. Each chiral center may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, as well as, their racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.


[0035] The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114-120 (1985): solid and broken wedges are used to denote the absolute configuration of a chiral element; wavy lines and single thin lines indicate disavowal of any stereochemical implication which the bond it represents could generate; solid and broken bold lines are geometric descriptors indicating the relative configuration shown but denoting racemic character; and wedge outlines and dotted or broken lines denote enantiomerically pure compounds of indeterminate absolute configuration. Thus, the formula X is intended to

encompass both of the pure enantiomers of that pair:




X


Means either pure R,S,R:



or pure S,R,S:



whereas



refers to a racemic mixture of S,R,S and S,S,R, i.e. having a trans relative configuration on the beta lactam ring.

[0036] The term "enantiomeric excess" is well known in the art and is defined for a resolution of ab ? a + b as

$$ee_a = \left(\frac{\text{conc. of } a - \text{conc. of } b}{\text{conc. of } a + \text{conc. of } b} \right) \times 100$$

[0037] The term "enantiomeric excess" is related to the older term "optical purity" in that both are measures of the same phenomenon. The value of ee will be a number from 0 to 100, zero being racemic and 100 being pure, single enantiomer. A compound which in the past might have been called 98% optically pure is now more precisely described as 96% ee; in other words, a 90% ee reflects the presence of 95% of one enantiomer and 5% of the other in the material in question.

[0038] The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion.

[0039] Terminology related to "protecting", "deprotecting" and "protected" functionalities occurs throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential treatment with a series of reagents. In that context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection" occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as "protecting groups". Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in

Organic Synthesis by T.W.Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapters entitled "Protection for the Hydroxyl Group, Including 1,2- and 1,3-Diols" (pages 10-86).

[0040] The abbreviations Me, Et, Ph, Tf, Ts and Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, toluensulfonyl and methanesulfonyl respectively. A comprehensive list of abbreviations utilized by organic chemists (i.e. persons of ordinary skill in the art) appears in the first issue of each volume of the Journal of Organic Chemistry. The list, which is typically presented in a table entitled "Standard List of Abbreviations" is incorporated herein by reference.

[0041] While it may be possible for the compounds of formula (I) to be administered as the raw chemical, it is preferable to present them as a pharmaceutical composition. According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0042] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration. The most suitable route may depend upon the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or solvate

thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

[0043] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

[0044] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide sustained, delayed or controlled release of the active ingredient therein.

[0045] The pharmaceutical compositions may include a "pharmaceutically acceptable inert carrier", and this expression is intended to include one or more inert excipients, which include starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents, and the like. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques, "Pharmaceutically acceptable carrier" also encompasses controlled release means.

[0046] Compositions of the present invention may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, and the like. Any such optional ingredient must, of course, be compatible with the compound of the invention to insure the stability of the formulation.

[0047] Examples of excipients for use as the pharmaceutically acceptable carriers and the pharmaceutically acceptable inert carriers and the aforementioned additional ingredients include, but are not limited to:

[0048] BINDERS: corn starch, potato starch, other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (*e.g.*, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch (*e.g.*, STARCH 1500® and STARCH 1500 LM®, sold by Colorcon, Ltd.), hydroxypropyl methyl cellulose, microcrystalline cellulose (*e.g.* AVICEL™, such as, AVICEL-PH-101™, -103™ and -105™, sold by FMC Corporation, Marcus Hook, PA, USA), or mixtures thereof;

[0049] FILLERS: talc, calcium carbonate (*e.g.*, granules or powder), dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate (*e.g.*, granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, or mixtures thereof;

[0050] DISINTEGRANTS: agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch

glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, other algin, other celluloses, gums, or mixtures thereof;

[0051] LUBRICANTS: calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil *e.g.*, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, syloid silica gel (AEROSIL 200, W.R. Grace Co., Baltimore, MD USA), a coagulated aerosol of synthetic silica (Deaussa Co., Plano, TX USA), a pyrogenic silicon dioxide (CAB-O-SIL, Cabot Co., Boston, MA USA), or mixtures thereof;

[0052] ANTI-CAKING AGENTS: calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc, or mixtures thereof;

[0053] ANTIMICROBIAL AGENTS: benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimersol, thymo, or mixtures thereof; and

[0054] COATING AGENTS: sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methyl cellulose phthalate, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnuba wax, microcrystalline wax, or mixtures thereof.

[0055] The dose range for adult humans is generally from 0.005 mg to 10 g/day orally.

Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10mg to 200mg. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.

[0056] Combination therapy can be achieved by administering two or more agents, each of which is formulated and administered separately, or by administering two or more agents in a single formulation. Other combinations are also encompassed by combination therapy. For example, two agents can be formulated together and administered in conjunction with a separate formulation containing a third agent. While the two or more agents in the combination therapy can be administered simultaneously, they need not be. For example, administration of a first agent (or combination of agents) can precede administration of a second agent (or combination of agents) by minutes, hours, days, or weeks. Thus, the two or more agents can be administered within minutes of each other or within 1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days of each other or within 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks of each other. In some cases even longer intervals are possible. While in many cases it is desirable that the two or more agents used in a combination therapy be present in within the patient's body at the same time, this need not be so. Combination therapy can also include two or more administrations of one or more of the agents used in the combination. For example, if agent X and agent Y are used in a combination, one could administer them sequentially in any combination one or more times, e.g., in the order X-Y-X, X-X-Y, Y-X-Y, Y-Y-X, X-X-Y-Y, etc.

[0057] In Vivo Assay of Hypolipidemic Agents using the Rat Cholesterol Absorption Model.

This model is based on models described by Burnett et al (2002), *Bioorg Med Chem Lett.* 2002 Feb 11;12(3):315-8 and *J Lipid Res.* 1999 Oct;40(10):1747-57. Female Sprague-Dawley rats weighing 150-200g are separated into groups of 3 and fasted overnight. The animals (4-6/group) are dosed perorally with 300µL test compounds in olive oil or suitable vehicle. Thirty minutes later, 3 microCuries ³H cholesterol per rat are delivered perorally in 300 µL olive oil. After three hours, 200 µL serum is collected, vortexed with scintillation fluid, and measured for radioactivity in a scintillation counter.

[0058] In Vivo Assay of Hypolipidemic Agents Using the Hyperlipidemic Hamster:

Hamsters are separated into groups of six and given a controlled cholesterol diet (Purina Chow #5001 containing 0.5% cholesterol) for seven days. Diet consumption is monitored to determine dietary cholesterol exposure in the face of test compounds. The animals are dosed with the test compound once daily beginning with the initiation of diet. Dosing is by oral gavage of 0.2mL of corn oil alone (control group) or solution (or suspension) of test compound in corn oil. All animals moribund or in poor physical condition are euthanized. After seven days, the animals are anesthetized by intramuscular (IM) injection of ketamine and sacrificed by decapitation. Blood is collected into vacutainer tubes containing EDTA for plasma lipid analysis and the liver excised for tissue lipid analysis. Lipid analysis is conducted as per published procedures [Schnitzer-Polokoff, R., et al, *Comp. Biochem. Physiol.*, 99A, 4, 665-670 (1991)] and data are reported as percent reduction of lipid versus control.


[0059] The bioabsorption of the compounds herein described may be examined using the Caco-2 cell monolayer model of Hilger *et al.* [*Pharm. Res.* 7, 902 (1990)].


[0060] In general, the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described below, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned here.

[0061] The starting materials, in the case of suitably substituted azetidinones, may be obtained by the methods described in WO 02/50027, WO 97/16424, WO 95/26334, WO 95/08532 and WO 93/02048, the disclosures of which are incorporated herein by reference.

Processes for obtaining the compounds of the invention are presented below.


[0062] Scheme I






The method for the preparation of cholesterol absorption inhibitors illustrated in Scheme I begins with the double protection of the phenolic and benzylic hydroxyl moieties as *tert*-butyldimethylsilyl ethers (TBS). The *bis*-TBS ether is then subjected to treatment with methanolic potassium fluoride, which effects a selective deprotection of the phenol hydroxyl to afford compounds of the general formula 2. Treatment of the protected phenols (2) with 4-fluoronitrobenzene in the presence of base provided the nitrophenyl ether derivatives 3 which were converted to the corresponding anilines (4) upon catalytic hydrogenation. Acylation of aniline 4 with chloro or bromoacetic acid gave the corresponding alpha-halo acetyl derivatives, which were condensed with amines to afford the ammonium salts that were deprotected to the cholesterol absorption inhibitors 5. Alternatively, the anilines 4 could be condensed with *alpha*-ammonium salts of acetic acid and then deprotected to give the desired inhibitors 5.

[0063] Scheme II



Scheme II illustrates the method that was used for the preparation of cholesterol absorption inhibitors that are isomeric with the derivatives described in Scheme I. The mono-protected phenol 6 was condensed with 4-fluoronitrobenzene to provide phenyl ethers 7. Catalytic hydrogenation of 7 afforded the corresponding anilines 8 which were converted into the cholesterol absorption inhibitors 9 as described in Scheme I.


[0064] Scheme III



Scheme III illustrates the preparation of cholesterol absorption inhibitors of the type exemplified by quaternary ammonium salt 10. The synthesis begins with the unprotected phenols of the formula 1. Treatment of 1 with α,α'-dibromo-*p*-xylene followed by


condensation with a tertiary amine afforded compounds of the formula 10. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 10 wherein $R_3 = \text{OH}$.

[0065] Scheme IV



Scheme IV illustrates the preparation of cholesterol absorption inhibitors of the type exemplified by quaternary ammonium salt 11. The synthesis begins with phenols of the formula 6. Treatment of 6 with α, α' -dibromo-*p*-xylene followed by condensation with a tertiary amine afforded compounds of the formula 11. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 11 wherein $R_3 = \text{OH}$.


[0066] Scheme V



Scheme V illustrates the method that was employed for the preparation of cholesterol absorption inhibitors of the type exemplified by structure 13. The synthesis commences with condensation of an acetylenic derivative with an iodo substituted derivative 12 under Sonogoshira reaction conditions. The acetylene-substituted products were then converted into


the corresponding ammonium salts (**13**) by quaternization of the appropriate bromide or sulfonate ester derivatives with an appropriate amine. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors **13** wherein $R_3 = \text{OH}$.

[0067] Scheme VI



Scheme VI illustrates the method that was employed for the preparation of cholesterol absorption inhibitors of the type exemplified by structure **15**. The synthesis commences with condensation of an acetylenic derivative with an iodo substituted derivative **14** under Sonogoshira reaction conditions. The acetylene-substituted products were then converted into the corresponding ammonium salts (**15**) by quaternization of the appropriate bromide or sulfonate ester derivatives with an appropriate amine. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors **15** wherein $R_3 = \text{OH}$.


[0068] Scheme VII



Scheme VII illustrates the method utilized for the preparation of cholesterol absorption


inhibitors of the type exemplified by structure 17. The sequence commences by coupling the aromatic iodide 12 with an appropriately substituted aryl or alkyl boronic acid by Suzuki reaction conditions. Conversion of the coupling product to the desired ammonium salts 17 was then accomplished by preparation of the corresponding aryl bromide or sulfonate ester derivatives followed by quaternization with an appropriate amine. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 17 wherein $R_3 = \text{OH}$.

[0069] Scheme VIII




Scheme VIII illustrates the method utilized for the preparation of cholesterol absorption inhibitors of the type exemplified by structure 19. The sequence commences by coupling the aromatic iodide 14 with an appropriately substituted aryl or alkyl boronic acid by Suzuki reaction conditions. Conversion of the coupling product to the desired ammonium salts 19 was then accomplished by preparation of the corresponding aryl bromide or sulfonate ester derivatives followed by quaternization with an appropriate amine. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 19 wherein $R_3 = \text{OH}$.

[0070] Scheme IX




Illustrated in Scheme IX is the method that was employed to prepare compounds of the general formula 21. The sequence commences with compound 1 or if desired the protected form 2 (from Scheme I) by treatment with α, α' -dibromo-*p*-xylene to afford the mono-bromo derivative 20. Treatment of 20 with the quaternary ammonium salt 10 where in R_7 , R_8 and R_9 are derived from an *N,N'* disubstituted piperazine derivative gave the desired *bis*-ammonium salts 21. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 21 wherein $R_3 = \text{OH}$.

[0071] Scheme X




Illustrated in Scheme X is the general method that was used for the preparation of *bis*-ammonium salts of the general formula 24. Treatment of α -bromoxylene derivatives (20) with an *N, N'* disubstituted piperazine derivative affords salts of the type 22. Condensation of the salts 22 with α -bromoxylene derivatives of the type 23 (prepared from phenols 6 and α, α' -dibromo-*p*-xylene) provides the desired *bis*-salts 24. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 24 wherein R₃ = OH.

[0072] Scheme XI




Illustrated in Scheme XI is the general method that was used for the preparation of *bis*-ammonium salts of the general formula 26. Treatment of α -bromoxylene derivatives (23) with an *N,N'*-disubstituted piperazine derivative affords salts of the type 25. Condensation of the salts 25 with α -bromoxylene derivatives 23 provides the desired *bis*-salts 26. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 26 wherein $R_3 = OH$.

[0073] Scheme XII




Illustrated in Scheme XII is the general method for the preparation of ammonium salts of the general formula 27. The method for the preparation of these analogues is catalytic hydrogenation of the corresponding acetylenic salts 13. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 27 wherein $R_3 = \text{OH}$.

[0074] Scheme XIII




Illustrated in Scheme XII is the general method for the preparation of ammonium salts of the general formula 28. The method for the preparation of these analogues is catalytic hydrogenation of the corresponding acetylenic salts 14. Deprotection of the benzylic TBS ether (if present) then affords the desired cholesterol absorption inhibitors 28 wherein $R_3 = \text{OH}$.

[0075] Scheme XIV



Illustrated in Scheme XIV is the general method that was employed for the preparation of carboxylic acids of the type exemplified by compound 30. The sequence commences with the conversion of phenols of the general formula 2 to their corresponding trifluoromethane sulfonate esters 29 upon treatment with *N*-phenyltrifluoromethanesulfonimide in the presence of triethylamine. The triflate 29 is then converted into a carboxylic acid by dissolving in dimethyl sulfoxide and treatment with carbon monoxide in the presence of palladium II acetate and 1,1-bis-(diphenylphosphino)ferrocene (dppf). Deprotection of the benzylic TBS ether then affords the desired cholesterol absorption inhibitors 30 wherein $R_3 = \text{OH}$. The carboxylic acids of the type 30 are also useful intermediates for the preparation of cholesterol absorption inhibitors.

[0076] Scheme XV




Illustrated in Scheme XV is the general method that was employed for the preparation of carboxylic acids of the type exemplified by compound 32. The sequence commences with the conversion of phenols of the general formula 2 to their corresponding trifluoromethane sulfonate esters 31 upon treatment with *N*-phenyltrifluoromethanesulfonimide in the presence of triethylamine. The triflate 31 is then converted into a carboxylic acid by dissolving in dimethyl sulfoxide and treatment with carbon monoxide in the presence of palladium II acetate and 1,1-bis-(diphenylphosphino)ferrocene (dppf). Deprotection of the benzylic TBS ether then affords the desired cholesterol absorption inhibitors 32 wherein $R_3 = OH$. The carboxylic acids of the type 32 are also useful intermediates for the preparation of cholesterol absorption inhibitors.

The trifluoromethane sulfonate esters 29 and 31 are also useful for the preparation of acetylene substituted cholesterol absorption inhibitors 13 and 15 by the Sonogoshira reaction.


In addition, the Suzuki coupling method may employ 29 and 31 as coupling partners for the preparation of cholesterol absorption inhibitors 17 and 19.

[0077] Scheme XVI



Illustrated in Scheme XVI is the general method for the preparation of cholesterol absorption inhibitors of the general formula 34. The synthesis commences with the coupling of a donor phenol 6 with an activated sugar derivative 33 to effect coupling to afford the protected compounds 34. The activating group may be, for example, $-\text{OCNHCCl}_3$. Subsequent deprotection, if desired, affords the cholesterol absorption compounds 34. Reactions for adding and deprotecting sugars are described in US patent 5,756,470, which is incorporated herein by reference.


[0078] Scheme XVII



Illustrated in Scheme XVI is the general method for the preparation of cholesterol absorption


inhibitors of the general formula **35**. The synthesis commences with the coupling of a donor phenol **2** with an activated sugar derivative **33** to effect coupling to afford the protected compounds **35**. Subsequent deprotection, if desired, affords the cholesterol absorption compounds **35**.

[0079] Scheme XVIII




Illustrated in Scheme XVIII is the general synthetic method for the preparation of cholesterol absorption inhibitors of the formula **36**. The method involves coupling of the carboxylic acids **30** with an amino substituted ammonium salt under amide forming conditions to afford the desired salts **36**. Alternatively, the acids **30** can be coupled with a tertiary amine containing primary amine followed by quaternization with an alkyl halide (R₇) to afford the salts **36**.

[0080] Scheme XIX




Illustrated in Scheme XIX is the general synthetic method for the preparation of cholesterol absorption inhibitors of the formula 37. The method involves coupling of the carboxylic acids 32 with an amino substituted ammonium salt under amide forming conditions to afford the desired salts 37. Alternatively, the acids 32 can be coupled with a tertiary amine containing primary amine followed by quaternization with an alkyl halide (R7) to afford the salts 37.

[0081] Scheme XX




Illustrated in Scheme XX is the general synthetic method for the preparation of cholesterol absorption inhibitors of the formula 39. The method involves coupling of the carboxylic acids 30 with a tertiary amine containing primary amine followed by quaternization with a *bis*-alkyl halide (represented by the X in structure 39) to afford the *bis*-salts 39. Examples of *bis*-alkyl halides would be useful for the preparation of the *bis*-salts 39 would be compounds such as 1,4-dibromobutane, 1,3-dibromopropane, α,α' -dibromo-*para*-xylene, α,α' -dibromo-*meta*-xylene and the like.

[0082] Scheme XXI




Illustrated in Scheme XXI is the general synthetic method for the preparation of cholesterol absorption inhibitors of the formula 41. The method involves coupling of the carboxylic acids 32 with a tertiary amine containing primary amine followed by quaternization with a bis-alkyl halide (represented by the X in structure 41) to afford the bis-salts 41. Examples of bis-alkyl halides would be useful for the preparation of the bis-salts 41 would be compounds such as 1,4-dibromobutane, 1,3-dibromopropane, α,α' -dibromo-*para*-xylene, α,α' -dibromo-*meta*-xylene and the like.

[0083] Scheme XXII




The compound illustrated in Scheme XXII as a *bis*-quaternary ammonium salt cholesterol absorption inhibitor, **42**. The preparation of **42** can be effected by treatment of a mixture of the tertiary amine containing derivatives **38** and **40** with a *bis*-alkyl halide. Examples of *bis*-alkyl halides would be useful for the preparation of the *bis*-salts **42** would be compounds such as 1,4-dibromobutane, 1,3-dibromopropane, α,α' -dibromo-*para*-xylene, α,α' -dibromo-*meta*-xylene and the like.

[0084] Preparation of 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1-azoniabicyclo[2.2.2]octane chloride



[0085] Step 1. Preparation of (3R,4S)-4-[4-(4-bromomethyl benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one




Cesium carbonate (344.7 mg, 1.06 mmol) was lightly flame-dried in a flame-dried flask. When cooled, N,N-dimethylformamide (DMF) (5.0 mL) was added via syringe followed by α,α' -dibromo-*p*-xylene (826.2 mg, 3.13 mmol) and finally (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one (254.1 mg, 0.621 mmol) both as solids. The reaction was stirred for 3 h at room temperature, diluted with ethyl acetate (20 mL), filtered through a pad of Celite® and washed with ethyl acetate (100 mL). The solution was transferred to a separatory funnel, washed with water (3 x 100 mL) and brine (50 mL), dried over sodium sulfate, filtered, concentrated and purified by chromatography (35 g silica gel, 10% to 90% ethyl acetate-hexane) to afford (3R,4S)-4-[4-(4-bromomethyl benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (265.3 mg, 72% yield) as a clear film.

[0086] Step 2. Preparation 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1-azoniabicyclo[2.2.2]octane chloride

The product from Step 1 (138.6 mg, 0.234 mmol) was dissolved in dry acetonitrile (1.0 mL). Quinuclidine (26.0 mg, 0.234 mmol) in 1.0 mL of dry acetonitrile was added to the bromide mixture and the reaction was stirred at room temperature for 5 h. The solution was concentrated, purified by reverse-phase HPLC (21mm column, 35% to 65% acetonitrile-0.1% trifluoroacetic acid in water), passed through Dowex® 21K Cl (chloride) anion exchange resin in methanol and concentrated to afford 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-


(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1-azoniabicyclo[2.2.2]octane chloride (137.3 mg, 92% yield) as a glassy solid.

[0087] Preparation of 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-4-aza-1-azoniabicyclo[2.2.2]octane bromide



(3R,4S)-4-[4-(4-bromomethyl benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (55.9 mg, 0.094 mmol) was dissolved in dry acetonitrile (2.0 mL). A solution of 1,4-diazabicyclo[2.2.2]octane (9.5 mg, 0.085 mmol) in 0.5 mL of dry acetonitrile was added to the bromide mixture, the reaction was stirred at room temperature for 3 h and then concentrated. The residue was partitioned between water (30mL) and 1:1 ethyl acetate-hexane (30 mL), shaken to form an emulsion and transferred to two 50-mL Falcon® tubes. The samples were spun at 3000 rpm for 25 min and the aqueous layers are removed carefully via pipette, combined, concentrated at 35 °C and azeotropically dried with methanol (20 mL) to afford 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-4-aza-1-azoniabicyclo[2.2.2]octane bromide (54.8 mg, 92% yield) as a clear film.


[0088] Preparation of 1,4-bis{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1,4-diazabicyclo[2.2.2]octane dibromide




1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-4-aza-1-azoniabicyclo[2.2.2]octane bromide (79.2 mg, 0.112 mmol) was dissolved in dry acetonitrile (1.0 mL). A solution of (3R,4S)-4-[4-(4-bromomethyl benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]azetidin-2-one (74.2 mg, 0.125 mmol) in 2 x 3 mL of dry acetonitrile was added to the amine solution, the reaction was stirred at 50 °C for 3 h and then concentrated. The supernatant was decanted off and the remaining residue at the bottom of the flask was triturated with water (20 mL) and ethyl acetate (20 mL) and then azeotropically dried with methanol (20 mL) to afford 1,4-bis{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1,4-diazoniabicyclo[2.2.2]octane dibromide (131.9 mg, 91% yield) as a clear glassy solid.

The invention is characterized as follows:

[0089] A compound of formula



or



wherein

R^1 and R^2 are chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl, lower aminoalkyl, alkylsulfonyl, arylsulfonyl, a sugar, a glucuronide and a sugar carbamate;

R^3 is chosen from H, -OH, fluoro and -O-loweralkyl;

R^{3a} is chosen from H and fluoro, or R^{3a} and R^3 together are =O;

R^4 is chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl and lower aminoalkyl, alkylsulfonyl, arylsulfonyl;

Q is chosen from a direct bond, -O-, -S-, -NH-, -CH₂O-, -CH₂NH-, -C(=O)-, -CONH-, -NHCO-, -O(C=O)-, -(C=O)O-, -NHCONH-, -OCONH- and -NHCOO- ;

A is chosen from C₂ to C₂₀ hydrocarbon, substituted alkyl of 2 to 20 carbons, substituted aryl, substituted arylalkyl, and oxaalkyl of four to fifty carbons; and, when Q is a direct bond, -C(=O) or -O(C=O)-, A may additionally be methylene;


R^5 forms a five- to seven-membered ring with A or R^6 ;


R^6 is alkyl, forms a double bond with A or forms a five- to seven-membered ring with R^5 ;

R^7 is alkyl or together with R^5 or R^6 forms a second five- to seven-membered ring; and when Q is not -O- or -CH₂NH-, R^5 may additionally be alkyl or aryl; and


X is an anion.

[0090] A compound chosen from three isomers of formulae:





and



wherein

R^1 and R^2 are chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl, lower aminoalkyl, alkylsulfonyl, arylsulfonyl, a sugar, a glucuronide and a sugar carbamate;

R^3 is chosen from H, -OH, fluoro and -O-loweralkyl;

R^{3a} is chosen from H and fluoro, or R^{3a} and R^3 together are =O;

R^4 is chosen from H, halogen, -OH, loweralkyl, -O-loweralkyl, -CN, -S-loweralkyl, amino, acyl and lower aminoalkyl, alkylsulfonyl, arylsulfonyl;

Q is chosen from a direct bond, -O-, -S-, -NH-, -CH₂O-, -CH₂NH-, -C(=O)-, -CONH-,

-NHCO-, -O(C=O)-, -(C=O)O-, -NHCONH-, -OCONH- and -NHCOO- ;

A is chosen from C₂ to C₂₀ hydrocarbon, substituted alkyl of 2 to 20 carbons, substituted aryl, substituted arylalkyl and oxaalkyl of four to fifty carbons; and, when Q is a direct bond, -C(=O) or -O(C=O)-, A may additionally be methylene;


Y is chosen from C₂ to C₂₀ hydrocarbon, substituted alkyl of 2 to 20 carbons, substituted arylalkyl and oxaalkyl of four to fifty carbons;


R⁶ and R^{6a} are alkyl or together with Y form a first five- to seven-membered ring;

R⁷ and R^{7a} are alkyl or together form a second five- to seven-membered ring; and


X₂ is either a dianion or two monoanions.

[0091] A compound according to paragraph [0090] chosen from three isomers of formulae:





and




[0092] A compound according to either of paragraphs [0089], [0090] or [0091] wherein R⁷ forms a second six-membered ring.

[0093] A compound according to any of paragraphs [0089] to [0092] wherein -Q-A- is chosen from (C₂ to C₂₀ hydrocarbon), -O-(C₂ to C₂₀ hydrocarbon), -NH(C₂ to C₂₀ hydrocarbon), -NHCO(C₂ to C₂₀ hydrocarbon) and oxaalkyl of four to fifty carbons.


[0094] A compound according to any of paragraphs [0089] to [0093] wherein
 R¹ and R² are chosen from H, halogen, -OH, and methoxy;
 R³ is -OH; and
 R⁴ is fluoro.


[0095] A compound according to any of paragraphs [0089] to [0093] wherein
 R¹ and R² are chosen from a sugar, a glucuronide and a sugar carbamate;
 R³ is -OH; and
 R⁴ is fluoro.

[0096] A compound according to any of paragraphs [0089] or [0092] to [0095] wherein R⁵, R⁶ and R⁷ taken together form a diazabicyclooctane quat:




[0097] A compound according to any of paragraphs [0089] or [0092] to [0095] wherein R⁵, R⁶ and R⁷ taken together form a quinuclidinium quat:






N:\USERS\2221 Microbia\2221004\TO PTO\2221004noclaim-app.doc
8/22/2003 4:38 PM


[00102] A compound according to any of paragraphs [0089] to [00101] wherein -Q-A- is




R⁷ is alkyl:




[00104] 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1-azoniabicyclo[2.2.2]octane chloride



[00105] 1-{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-4-aza-1-azoniabicyclo[2.2.2]octane



[00106] 1,4-bis{4-[(4-{(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl}phenoxy)methyl]benzyl}-1,4-diazoniabicyclo[2.2.2]octane



[00107] A compound according to any of paragraphs [0089] to [00106] wherein X or X₂ is a pharmaceutically acceptable anion.

[00108] A compound according to paragraph [00107] wherein X is an anion chosen from the group consisting of hydroxide, acetate, benzenesulfonate (besylate), benzoate, bicarbonate, bisulfate, carbonate, camphorsulfonate, citrate, ethanesulfonate, fumarate, gluconate, glutamate, bromide, chloride, isethionate, lactate maleate, malate, mandelate, methanesulfonate, mucate, nitrate, pamoate, pantothenate, phosphate, succinate, sulfate, tartrate and p-toluenesulfonate.

[00109] A compound according to any of paragraphs [0090]-[0095], [0098], [00100], [00101] or [00107] wherein X₂ is a dianion chosen from the group consisting of carbonate, citrate, fumarate, lactate, maleate, malate, phosphate, succinate, sulfate and tartrate.

[00110] A pharmaceutical formulation comprising a compound according to any of paragraphs [00107]-[00109] and a pharmaceutically acceptable carrier.

[00111] A pharmaceutical formulation according to paragraph [00110] additionally comprising an inhibitor of cholesterol biosynthesis.

[00112] A method for treating a disorder of lipid metabolism comprising administering a to a mammal a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109]

[00113] A method according to paragraph [00112], wherein said disorder of lipid metabolism is hyperlipidemia.

[00114] A method according to paragraph [00112], wherein said disorder of lipid metabolism is arteriosclerosis.

[00115] A method for inhibiting the absorption of cholesterol from the intestine of a mammal, which comprises administering an effective cholesterol-absorption-inhibiting amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00116] A method for reducing the blood plasma or serum concentrations of LDL cholesterol in a mammal, which comprises administering an effective cholesterol reducing amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00117] A method for reducing the concentrations of cholesterol and cholesterol ester in the blood plasma or serum of a mammal, which comprises administering an effective cholesterol and cholesterol ester reducing amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00118] A method for increasing the fecal excretion of cholesterol in a mammal, which comprises administering an effective cholesterol fecal excretion increasing amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00119] A method for the prophylaxis or treatment of a clinical condition in a mammal, for which a cholesterol uptake inhibitor is indicated, which comprises administering a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00120] A method for reducing the incidence of coronary heart disease-related events in a mammal, which comprises administering an effective coronary heart disease-related

events reducing amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00121] A method for reducing the concentration of cholesterol in the blood plasma or serum of a mammal, which comprises administering an effective cholesterol reducing amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00122] A method for reducing blood plasma or serum concentrations of C-reactive protein (CRP) in a mammal, which comprises administering a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00123] A method for reducing blood plasma or serum concentrations of triglycerides in a mammal, which comprises administering a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.



[00124] A method for increasing blood plasma or serum concentrations of HDL cholesterol of a mammal, which comprises administering a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

[00125] A method for reducing blood plasma or serum concentrations of apolipoprotein B, in a mammal, which comprises administering a therapeutically effective amount of a compound according to any of paragraphs [00107]-[00109] to the mammal.

QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES

Abstract of the Disclosure

Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formulae



as well as isomers of these formulae.

APPLICATION DATA SHEET

Electronic Version 0.0.11

Stylesheet Version: 1.0

Publication Filing Type: Provisional

Application Type: Provisional

Title of Invention: QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES

Legal Representative:

Attorney or Agent: Philip E. Hansen

Registration Number: 32700

Customer Number Correspondence Address: 23405

23405

INVENTOR(s):

Primary Citizenship: UNITED STATES

Given Name: Eduardo

Middle Name: J.

Family Name: Martinez

Residence City: Boston

Residence State: MA

Residence Country: US

Address: 271 North Street, Apt. 1
Boston MA, 02113-2107 US

Primary Citizenship: UNITED STATES

Given Name: John

Middle Name: Jeffrey

Family Name: Talley

Residence City: Somerville

Residence State: MA

Residence Country: US

Address: 96 North Street, #3

Somerville MA, 02144 US

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/027540

International filing date: 25 August 2004 (25.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/497,590
Filing date: 25 August 2003 (25.08.2003)

Date of receipt at the International Bureau: 30 September 2004 (30.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse